CERS earnings call for the period ending March 31, 2019.
News & Analysis: Cerus
CERS earnings call for the period ending December 31, 2018.
Preliminary third-quarter results pleased the crowd at the company's annual investor meeting.
A better-than-expected outlook after the company's first-quarter report is lifting more than spirits.
Positive pivotal trial results bode well for the company's new blood transfusion product.
The biopharma reported third-quarter 2017 results and additional business updates.
A positive regulatory development sent Cerus' shares higher today.
The company provided an update on the most pressing issue facing the biopharma stock in 2017.
Even with today's pop, the stock is near six-year lows.
Investors headed for the exits after the company announced an unexpected product supply shortage.